ResMed successfully defends key patents against NYU’s claims
ResMed (ASX:RMD) announced on Tuesday that the US Patent Trial and Appeals Board has dismissed claims filed by New York University (NYU) related to the company's patents.
Read MoreTag: RMD
Sleepless Nights for Rivals after Philips Warning
Concerns for Resmed and Fisher and Paykel Healthcare after a surprise profit warning from Philips, their big Dutch rival in the sleep and respiratory sectors, saw its share price hit 10-year lows.
Read MoreResmed Puts German Software Deal to Bed
After two smaller buys in this area in the past few years, Resmed has made a major deal to buy German out-of-hospital software solutions leader Medifox Dan for $US1 billion.
Read MoreRMD – Morgans rates the stock as Add
The broker retains its Add rating and reduces its target price to $40.80 from $41.34.
Read MoreRMD – Citi rates the stock as Neutral
The broker retains its Neutral rating and $36.50 target price.
Read MoreRMD – Credit Suisse rates the stock as Outperform
The analyst thinks recent share underperformance provides significant valuation upside. The $44 target price and Outperform rating are unchanged.
Read MoreGrowth For ResMed Despite Challenges
Growth in masks and accessories has prevailed for ResMed despite pandemic-induced restrictions, although cycling the surge in ventilator sales from early 2020 will be a challenge.
Read MoreRMD – UBS rates the stock as Buy
ResMed will report its second-quarter results on January 29, 2021. UBS expects revenue growth to be 5.2% for the US, Canada and Latin America. The Buy rating is unchanged with a target of $US241.
Read MoreRMD – UBS rates the stock as Buy
UBS incorporates a 10% share buyback into forecasts, after assuming no major increases in debt levels due to any significant near-term acquisitions. The Buy rating is unchanged. The target price is increased to $US241 from US$210.
Read MoreRMD – Morgans rates the stock as Add
Resmed’s first quarter was above Morgans expectations, underpinned by high single digit revenue growth and expanding gross margins, with lower operating expenses driving ongoing operating leverage.
Read MoreRMD – UBS rates the stock as Neutral
ResMed will report its first-quarter results on 30 October. UBS forecasts revenue growth for US/Canada/Latin America to be 3%. Europe and Asia are expected to show a revenue growth of 5%. Gross margin is expected to be flat versus the fourth quarter and net profit is forecast to be up 12% versus last year.
Read MoreBeyond vaccines
Trying to pick the winner of the COVID-19 vaccine race is as difficult as picking a winner during the spring carnival.
Read MoreWhy The ResMed Share Price Is Set To Recover
While the reasons for the decline 18 months ago are different to those underpinning the most recent sell-off, Michael Gable of Fairmont Equities considers that there are a number of factors supporting a recovery in Resmed shares this time around.
Read MoreRMD – UBS rates the stock as Neutral
UBS has analysed the current penetration of the US obstructive sleep apnoea (OSA) market and assessed the sustainability of new patient flow generator set-up growth.
Read MoreIs There A Slowdown Ahead For ResMed?
Brokers believe ResMed is reliant on pandemic-related ventilator sales offsetting any slump in the base sleep apnoea business.
Read MoreRMD – Credit Suisse rates the stock as Neutral
ResMed reports its March quarter results on May 1. Credit Suisse expects third-quarter revenue growth of 6%.
Read MoreRMD – Macquarie rates the stock as Underperform
Macquarie has long maintained the mantra that ResMed’s valuation, now 36.8x forward earnings and a 38% premium to medical device peers, ascribes limited medium-term risk in relation to reimbursement changes or the longer-term impact of competing technologies. Underperform retained.
Read MoreRMD – UBS rates the stock as Buy
Ahead of ResMed’s Sep Q results, the broker has made adjustments for forex and tax assumptions, leading to modest earnings downgrades. Target unchanged at US$140 (A$20.75 at current spot).
Read MoreRMD – Deutsche Bank rates the stock as Buy
March quarter results alleviated concerns that growth was slowing in the core sleep business. The company is achieving a benefit from fixed cost leverage, with Deutsche Bank noting EBITDA margin expansion of 106 basis points.
Read MoreRMD – Deutsche Bank rates the stock as Buy
Deutsche Bank attended the investor briefing in the US. The focus of the briefing was on addressing some of the issues raised in the second quarter results. More insights were provided into the Verily joint venture with an overview of the Propeller Health acquisition.
Read MoreRMD – UBS rates the stock as Neutral
UBS delves into the financial implications of the company’s recent software-as-a-service/connected care acquisitions and joint ventures.
Read MoreResMed In US Software Company Acquisition
ResMed has slipped out plans on spending $US750 million ($A1.06 billion) on MatrixCare, which is long-term post-acute care software used by 15,000 health centres in the US.
Read MoreResmed Upbeat On Stronger Q2 Sales
Resmed (RMD) shares jumped more than 9% yesterday after the medical device maker lifted second-quarter revenue 17% to $US530 million, helped by income from the Brightree business it acquired in 2016. Quarterly dividend of 33 US cents a share, was up 10% from 30 US cents.
Read MoreResmed Pounded On Trial Failure
Resmed (RMD) shares took a pounding on the ASX yesterday after being sold off in the US in the wake of a poor result from a research trial.
Read MoreResMed Down, But Solid
Shares in medical equipment maker ResMed Inc ended the day off 12% after surprising with a sharp fall in quarterly earnings due in most part to the stronger Australian dollar.
Read MoreResmed Disappoints
ResMed Inc is an Australian/US company which is the world's second-biggest maker of products to treat sleep disorders.
Read More
